Literature DB >> 2608572

Fatal torsade de pointes following jaundice in a patient treated with disopyramide.

A Schattner1, J Gindin, D Geltner.   

Abstract

A case of fatal torsade de pointes in a 53 year old patient treated with disopyramide is described. The arrhythmia followed the development of acute hepatocellular dysfunction and may have been due to failure of the liver to efficiently degrade the drug to its metabolites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2608572      PMCID: PMC2429309          DOI: 10.1136/pgmj.65.763.333

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  6 in total

1.  Disopyramide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

2.  Disopyramide-induced QT prolongation and ventricular tachyarrhythmias.

Authors:  N Riccioni; M Castiglioni; C Bartolomei
Journal:  Am Heart J       Date:  1983-05       Impact factor: 4.749

3.  Fatal overdosage with disopyramide.

Authors:  A M Hayler; D W Holt; G N Volans
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

4.  Unusual hepatocellular and cardiovascular complications of disopyramide.

Authors:  A M Tonkin; S E Joel; J L Reynolds
Journal:  Chest       Date:  1980-01       Impact factor: 9.410

5.  Disopyramide and cholestasis.

Authors:  A Craxi; G Gatto; A Maringhini; S Orsini; G Pinzello; L Pagliaro
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

Review 6.  "Les torsades de pointes": an unusual ventricular arrhythmia.

Authors:  W M Smith; J J Gallagher
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

  6 in total
  2 in total

1.  A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Authors:  C L Lawrence; M H Bridgland-Taylor; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

Review 2.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.